Is Ibrance being discontinued?

As of Oct 24, 2026, FDA lists discontinuation notices for Palbociclib Capsule, not a shortage. A discontinuation “does not necessarily create a shortage” (FDA).

When will the Ibrance shortage end?

FDA gives no end date, and no manufacturer posted a recovery estimate for this listing.

Does FDA list alternatives to Ibrance?

No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.

Is Ibrance (Palbociclib Capsule) being discontinued?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

DISCONTINUATION NOTICE

Ibrance: being discontinued (FDA, Oct 24)

Capsules

A generic capsule, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.

DRUG

Ibrance

FDA LISTING

Palbociclib Capsule

FORM

capsules

STATUS

Discontinuation

FIRST POSTED

Apr 22, 2026

LAST FDA UPDATE

Apr 22, 2026

AS OF

Oct 24, 2026

SOURCE

FDA Drug Shortages ↗ (opens in a new tab)

1 discontinuation notice below, in FDA's words. A discontinuation “does not necessarily create a shortage” (FDA).

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Palbociclib Capsule. 2 presentations from 1 maker.

Check your own medication, form and strength

What to ask at the counter

Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
Is my strength or the maker you stock affected? FDA list, by presentation
Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Discontinuation notices

A discontinuation “does not necessarily create a shortage” (FDA).

Pfizer Inc. told FDA it will discontinue Ibrance (posted Apr 22, 2026).
“Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.”
FDA listing: Palbociclib Capsule

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Ibrance being discontinued?: As of Oct 24, 2026, FDA lists discontinuation notices for Palbociclib Capsule, not a shortage. A discontinuation “does not necessarily create a shortage” (FDA).
When will the Ibrance shortage end?: FDA gives no end date, and no manufacturer posted a recovery estimate for this listing.
Does FDA list alternatives to Ibrance?: No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.